Richard William Scalzo Sells 1,343 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) SVP Richard William Scalzo sold 1,343 shares of the business’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $11.38, for a total value of $15,283.34. Following the sale, the senior vice president now owns 122,330 shares of the company’s stock, valued at approximately $1,392,115.40. This represents a 1.09 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Dyne Therapeutics Price Performance

Shares of DYN opened at $12.05 on Friday. The firm has a market cap of $1.36 billion, a P/E ratio of -3.38 and a beta of 1.11. Dyne Therapeutics, Inc. has a 1 year low of $11.18 and a 1 year high of $47.45. The company has a 50 day simple moving average of $14.83 and a two-hundred day simple moving average of $25.63.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.04. On average, sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Hedge Funds Weigh In On Dyne Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DYN. FMR LLC raised its holdings in shares of Dyne Therapeutics by 69.7% during the 3rd quarter. FMR LLC now owns 9,026,697 shares of the company’s stock worth $324,239,000 after acquiring an additional 3,707,734 shares in the last quarter. Janus Henderson Group PLC increased its position in Dyne Therapeutics by 47.3% in the third quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company’s stock worth $244,755,000 after purchasing an additional 2,189,339 shares during the last quarter. Jefferies Financial Group Inc. purchased a new stake in Dyne Therapeutics during the fourth quarter valued at $42,408,000. Norges Bank bought a new position in Dyne Therapeutics during the fourth quarter valued at $22,384,000. Finally, Point72 Asset Management L.P. grew its stake in shares of Dyne Therapeutics by 802.3% in the 4th quarter. Point72 Asset Management L.P. now owns 924,681 shares of the company’s stock worth $21,785,000 after buying an additional 822,201 shares in the last quarter. 96.68% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on DYN. Piper Sandler dropped their price objective on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. Robert W. Baird assumed coverage on shares of Dyne Therapeutics in a research report on Friday, December 13th. They set an “outperform” rating and a $46.00 price objective for the company. BMO Capital Markets started coverage on Dyne Therapeutics in a report on Wednesday. They issued an “outperform” rating and a $50.00 target price on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $45.00 price target on shares of Dyne Therapeutics in a report on Tuesday, January 14th. Finally, Baird R W raised Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $48.85.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.